Mirvetuximab soravtansine (Elahere) FDA approval (2022)
AbbVie's Elahere became the first FRα-directed antibody-drug conjugate approved by the FDA, for platinum-resistant ovarian cancer patients with high FRα expression. The approval was based on the SORAYA trial in heavily pre-treated patients.
Gave a targeted option to patients who had exhausted chemotherapy alternatives.
Validated FRα as a druggable target while leaving patients with lower FRα expression without a matching therapy.
Sofe-M is designed to work regardless of FRα expression levels, directly addressing the patient-selection limitation that constrained Elahere's reach.
